Adocia Announces Its Financial Calendar For 2021
December 21 2020 - 12:00PM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
diabetes treatment with innovative formulations of approved
proteins, announced today its financial calendar for 2021.
March 18, 2021:
Publication of 2020 financial statements
(the Universal Registration Document will be released during Q2
2021).
April 21, 2021:
Publication of revenue for Q1 2021.
May 20, 2021:
Annual shareholders’ meeting.
September 7, 2021:
Publication of mid-year financial
statements as of June 30, 2021.
October 26, 2021:
Publication of revenue for Q3 2021.
In addition to regular meetings with the financial community,
investors can also find updated information on the company’s
website (www.adocia.com). All corporate information on the company
such as its financial statements, its corporate presentation and
its status is available on the company’s website, in the Investors’
section, « Regulated Information ».
About ADOCIA
ADOCIA is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, ADOCIA’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring four clinical-stage products. ADOCIA
aims to expand its portfolio towards the treatment of other
metabolic diseases and their comorbidities. The proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use. ADOCIA customizes BioChaperone to
each protein for a given application.
ADOCIA’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid-acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram (ADO09). The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
ADOCIA preclinical pipeline includes three products: a
combination of rapid human insulin analogues and Pramlintide
(BioChaperone LisPram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the
treatment of diabetes and a ready-to-use combination of glucagon
and a GLP-1 receptor agonist (BioChaperone® Glucagon GLP1) for the
treatment of obesity.
Disclaimer
This press release contains certain forward-looking statements
concerning ADOCIA and its business. Such forward-looking statements
are based on assumptions that ADOCIA considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 22, 2020 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions financial markets and the markets in which
ADOCIA operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance, or achievements of ADOCIA to be materially
different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
ADOCIA shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201221005329/en/
ADOCIA Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG ADOCIA Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group ADOCIA Investor Relations USA James
Salierno Vice-President jsalierno@theruthgroup.com Ph.: +1 646
536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Sep 2023 to Sep 2024